Midi Health, a clinic specialising in midlife women's health, is joining forces with Neurotrack, a digital cognitive assessment company, to assist women in distinguishing between brain fog symptoms associated with menopause and those indicating more severe cognitive issues like early dementia. Midi Health clinicians will utilise Neurotrack's cognitive screening, which patients can conveniently complete on their smartphones, tablets, or computers in just three minutes, significantly reducing the time traditionally required for such assessments.
If patients receive low scores on the Neurotrack test, they will be referred to providers for further detailed evaluation. According to Kathleen Jordan, Chief Medical Officer of Midi Health, brain fog during menopause is widespread, affecting 74 percent of Midi patients, akin to the prevalence of hot flashes. She emphasises that experiencing brain fog does not necessarily correlate with an increased likelihood of developing dementia, as studies indicate. Nonetheless, early detection of dementia is crucial for effective treatment, making Neurotrack's screening valuable in identifying potential cases.
Midi Health, based in California, recently secured $25 million in Series A funding, with plans to expand its services nationwide. The funding round, led by Google Ventures, brings the company's total raised capital to $50 million. Meanwhile, Neurotrack, headquartered in Silicon Valley, raised $10 million in 2022 and has partnered with insurance provider Nationwide to streamline long-term care underwriting, replacing the former 20-minute telephone screening with Neurotrack's quicker and more efficient process.
Click here to read the original news story.